MaximilianDiehnMD

Radiation Oncology • Stanford, CA

Thoracic Cancer

Associate Professor, Radiation Oncology, Stanford University Medical Center

Join to view full profile

Dr. Diehn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Diehn's full profile

Already have an account?

Office
875 Blake Wilbur Dr
Dept of Radiation Oncology Mc5847
Stanford, CA 94305
Phone+1 650-723-6171

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 2005 - 2009
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2004 - 2005
Stanford University School of MedicineClass of 2004

Certifications & Licensure

CA State Medical License 2005 - 2025
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) Start of enrollment: 2011 Oct 21
COMPLETED
NA
Molecular and Cellular Analysis of Breast Cancer
SUSPENDED
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Start of enrollment: 2021 Aug 25
Recruiting
Phase 3

Publications & Presentations

PubMed

A Phase 2 Single-Arm Trial of High-Dose Precision Targeted Radiation Therapy Added to Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer.
Michael F Gensheimer, Nikhil V Kotha, Lucas K Vitzthum, Alexander L Chin, Scott Jackson
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01
A vision-language foundation model for precision oncology.
Jinxi Xiang, Xiyue Wang, Xiaoming Zhang, Yinghua Xi, Feyisope Eweje
Nature. 2025-02-01
1 citations
Automated Deep Learning-Based Detection and Segmentation of Lung Tumors at CT.
Mehr Kashyap, Xi Wang, Neil Panjwani, Mohammad Hasan, Qin Zhang
Radiology. 2025-01-01

Abstracts/Posters

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Methods and Applications of cfDNA Analysis
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Can Cancer Be Found in a Blood Test?February 8th, 2023
Tool Can Reveal Cancer Subtypes by Cell Communities They’re Found InOctober 28th, 2021
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerMarch 30th, 2020
Join now to see all

Grant Support

Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapySTANFORD UNIVERSITY2024–2029
Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
Circulating Genomic Determinants of Treatment Failure in Hodgkin LymphomaSTANFORD UNIVERSITY2021–2026
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancerSTANFORD UNIVERSITY2020–2025
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancerSTANFORD UNIVERSITY2019–2024